Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel and Temozolomide in Progressive GEP-NETs
NCT02231762Phase 2Completed
- Sponsor
- Ipsen
- Start
- Oct 2014
- Primary completion
- Dec 2016
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, open-label trial of lanreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Ipsen. Primary endpoint: Disease Control Rate at 6 months. Started Oct 2014; status: completed.
02
Drugs
lanreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02231762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231762.